News & Events

  • November 08, 2017

    Ellex Medical Lasers Limited announced the closing of their PIPE offering in the amount of $23,000,000.  EG&S acted as counsel to Maxim Group LLC, the lead placement agent in the offering.

  • November 06, 2017

    Bio-Path Holdings, Inc. announced the closing of their PIPE in the amount of $9,000,000.  EG&S acted as counsel to the Placement Agent.

  • November 03, 2017

    Nemus Biosciences, Inc. announced the closing of their PIPE offering in the amount of $2,000,000.  EG&S acted as counsel to the sole investor.

  • November 03, 2017

    M III Acquisition Corp. announced that it has entered into a definitive agreement and plan of merger with IEA Energy Services LLC, a leading engineering, procurement and construction company in the renewable energy sector.  MIII will be renamed as "Infrastructure and Energy Alternatives, Inc." upon consummation of the merger and is expected to continue to be listed on the Nasdaq Capital Market under the symbol "IEA".  EG&S acted as special SPAC counsel to MIII.

  • November 02, 2017

    Global Partner Acquisition Corp. (“GPAC”) and Purple Innovation, LLC (“Purple”) announced that they have entered into a definitive merger agreement pursuant to which Purple will become a subsidiary of GPAC, based on an initial enterprise value of Purple of approximately $900 million. The consummation of the merger will be subject to the terms and conditions set forth in the agreement.  EG&S acted as counsel to GPAC.

  • October 31, 2017

    NeuroMetrix Inc. announced the closing of their PIPE offering in the amount of $3,500,000.  EG&S acted as counsel to the Lead Investor.

  • October 30, 2017

    Atossa Genetics Inc., a clinical-stage pharmaceutical company, announced the closing of its underwritten public offering in the amount of $5,500,000.  EG&S acted as counsel to Maxim Group LLC, the sole book-running manager for the offering.

  • October 27, 2017

    Social Reality Inc. announced the closing of their PIPE offering in the amount of $5,000,000. EG&S acted as counsel to the Lead Investor.

  • October 24, 2017

    Synthesis Energy Systems Inc. announced the closing of their PIPE offering in the amount of $15,000,000.  EG&S acted as counsel to the Lead Investor.

  • October 24, 2017

    Haymaker Acquisition Corp. announced the closing of its initial public offering in the amount of $300,000,000.  EG&S acted as counsel to Haymaker.

  • October 23, 2017

    Immune Pharmaceuticals Inc., a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, announced the closing of an underwritten public offering in the amount of $18,000,000.  The offering was comprised of Series E Convertible Preferred Stock and warrants.  EG&S acted as counsel to Maxim Group LLC, the sole book-running manager in the offering.

  • October 23, 2017

    Bloomberg published an article titled "2017 IPOs Are Larger and Faster" which analyzes the IPO market activity for the first three quarters of 2017.  In the Diversified sector, Ellenoff Grossman & Schole led with 11 IPOs that raised a total of $2.10 billion, but Weil Gotshal & Manges participated in six IPOs that totaled $3.55 billion. Venable led the Financial sector with seven IPOs that raised a total of $2.76 billion. The Industrial sector was dominated by Latham & Watkins and Simpson Thacher & Bartlett, while the Technology sector was led by Wilson Sonsini Goodrich & Rosati.

    Click here to read the full article.

  • October 20, 2017

    Connekt Media Inc. announced the closing of their bridge loan in the amount of $2,000,000.  EG&S acted as counsel to the Investor.

  • October 17, 2017

    CASI Pharmaceuticals Inc. announced the closing of their Registered Direct offerings in the amount of $23,855,595.  EG&S acted as counsel to the Placement Agent.

  • October 13, 2017

    Intellipharmaceutics International Inc. announced the closing of their Registered Direct offering in the amount of $4,000,000.  EG&S acted as counsel to the Placement Agent.

     

  • October 12, 2017

    Cellectar Biosciences Inc. announced the closing of their Registered Direct offering in the amount of $7,766,164.  EG&S acted as counsel to the Placement Agent.

  • October 11, 2017

    Rimini Street, Inc., a global provider of enterprise software products and services, announced the closing of its merger with special purpose acquisition company GP Investments Acquisition Corp. The combined company will retain the Rimini Street, Inc. name and will trade on Nasdaq as “RMNI.”  The transaction was valued at $50,000,000. Cowen served as financial and capital markets advisor to Rimini Street, and EG&S acted as counsel to Cowen.

  • October 04, 2017

    Jaguar Health, Inc. announced the closing of its public underwritten offering of common stock in the amount of $4,250,000.   EG&S acted as counsel to the underwriter, Maxim Group, LLC.

  • October 04, 2017

    Aethlon Medical, Inc. announced the closing of their Registered Direct offering in the amount of $6,000,000.  EG&S acted as counsel to the Placement Agent.

  • October 03, 2017

    The Deal's exclusive League Table ranking tracks PIPEs that raise at least $1 million between January 1 and September 15, 2017.  Ellenoff Grossman & Schole LLP was the top-ranked agent legal counsel with eight placements advised and tied for second, with four placements advised for investor legal counsel.

    Click here to read the full report.

  • October 02, 2017

    Nacuity Pharmaceuticals, Inc. announced the closing of their private placement of preferred stock and warrants in the amount of $9,422,000 over three closings.  EG&S acted as counsel to Maxim Group LLC.

  • October 02, 2017

    Rosetta Genomics announced the closing of their PIPE offering in the amount of $2,000,000.  EG&S acted as counsel to the Investor.

  • September 25, 2017

    China National Heavy Duty Truck Group Co. Ltd. announced that it has acquired 9.9% of UQM Technologies, Inc. (NYSE American: UQM) and has agreed to acquire an additional 24.1% of UQM subject to approval by the U.S. Committee on Foreign Investment in the United States (“CFIUS”). EGS is acting as counsel to CNHTC.

  • September 22, 2017

    Inspyr Therapeutics Inc. announced the closing of their Registered Direct offering in the amount of $1,750,000.  EG&S acted as counsel to the Placement Agent.

  • September 22, 2017

    DelMar Pharmaceuticals announced the closing of their Registered Direct offering in the amount of $10,000,000.  EG&S acted as counsel to the Placement Agent.